We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-2.24%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
+$368M
Cap. Flow
+$592M
Cap. Flow %
35.11%
Top 10 Hldgs %
42.19%
Holding
93
New
24
Increased
33
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$82.5M
2
APLT
Applied Therapeutics
APLT
+$64.9M
3
NUVL
Nuvalent
NUVL
+$56M
4
VERA icon
Vera Therapeutics
VERA
+$47.6M
5
CYTK icon
Cytokinetics
CYTK
+$44.1M

Top Sells

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$63.9M
2
INSM icon
Insmed
INSM
+$50.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$33.8M
4
JANX icon
Janux Therapeutics
JANX
+$22M
5
EW icon
Edwards Lifesciences
EW
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
51
Intellia Therapeutics
NTLA
$1.62B
$6.12M 0.36%
+525,000
New +$8.19M
OKUR
52
OnKure Therapeutics
OKUR
$166M
$5.46M 0.32%
635,000
+555,060
+694% +$8.4M
LKFT
53
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$4.95M 0.29%
180,000
– –
CMRX
54
DELISTED
Chimerix, Inc.
CMRX
$4.87M 0.29%
1,400,000
– –
STRO icon
55
Sutro Biopharma
STRO
$417M
$4.73M 0.28%
+257,000
New +$7.85M
VTYX
56
DELISTED
Ventyx Biosciences
VTYX
$4.38M 0.26%
2,000,000
+275,000
+16% +$623K
FATE icon
57
Fate Therapeutics
FATE
$294M
$4.07M 0.24%
2,465,000
+780,000
+46% +$1.97M
ANRO icon
58
Alto Neuroscience
ANRO
$1.11B
$3.87M 0.23%
915,000
+265,000
+41% +$1.65M
VERV
59
DELISTED
Verve Therapeutics
VERV
$3.64M 0.22%
645,000
+120,000
+23% +$677K
PASG icon
60
Passage Bio
PASG
$14.1M
$3.46M 0.21%
305,000
– –
ALLO icon
61
Allogene Therapeutics
ALLO
$687M
$3.19M 0.19%
1,500,000
– –
TMDX icon
62
Transmedics
TMDX
$2.78B
$3.12M 0.18%
+50,000
New +$4.65M
GLUE icon
63
Monte Rosa Therapeutics
GLUE
$1.35B
$2.95M 0.17%
425,000
-505,000
-54% -$3.79M
ZYME icon
64
Zymeworks
ZYME
$1.76B
$2.71M 0.16%
185,000
-430,000
-70% -$6.01M
ENGN icon
65
enGene Therapeutics
ENGN
$121M
$2.46M 0.15%
+370,000
New +$2.87M
BHC icon
66
Bausch Health
BHC
$2.22B
$2.02M 0.12%
+250,000
New +$2.06M
NGNE icon
67
Neurogene
NGNE
$707M
$1.83M 0.11%
+80,000
New +$2.98M
ACHL
68
DELISTED
Achilles Therapeutics
ACHL
$1.71M 0.1%
1,500,000
– –
ATRA icon
69
Atara Biotherapeutics
ATRA
$74.7M
$1.66M 0.1%
125,000
+323
+0.3% +$3.4K
IMVT icon
70
Immunovant
IMVT
$8.29B
$1.11M 0.07%
+45,000
New +$1.28M
MGNX icon
71
MacroGenics
MGNX
$250M
$910K 0.05%
280,000
-550,000
-66% -$1.98M
TRAW icon
72
Traws Pharma
TRAW
$8.15M
$666K 0.04%
+75,000
New +$417K
TENX icon
73
Tenax Therapeutics
TENX
$497M
$342K 0.02%
55,189
-28,144
-34% -$137K
AGIO icon
74
Agios Pharmaceuticals
AGIO
$1.92B
– –
-760,000
Closed -$33.8M
APGE icon
75
Apogee Therapeutics
APGE
$10.2B
– –
-136,500
Closed -$8.02M
1 2
3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Vestal Point Capital held 93 positions worth $1.69B, up 28% from $1.32B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Vestal Point Capital deployed $592M of net new capital in Q4 2024, opening 24 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 800,000 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $50.4M trimmed.

  • Vestal Point Capital's largest Q4 2024 buy was Merck: 800,000 shares worth $79.6M.
  • Vestal Point Capital added most to Applied Therapeutics in Q4 2024, an estimated $64.9M increase.
  • Vestal Point Capital's biggest Q4 2024 reduction was Insmed, cutting an estimated $50.4M.
  • Vestal Point Capital fully exited Inari Medical, Inc. Common Stock in Q4 2024, selling an estimated $63.9M.
  • Vestal Point Capital's ten largest holdings make up 42% of its $1.69B portfolio in Q4 2024.
  • Vestal Point Capital opened 24 new positions and closed 20 in Q4 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.69B.

Based on Vestal Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.